14TH ANNUAL MEETING EXHIBITOR AND SUPPORTER MEDIA GUIDE
ABLE/BIOTT
Page #
3
Ajinomoto Co., Inc.
4
AllCells
5
ALSTEM, LLC
6
Axion BioSystems
7
Axol Bioscience
8
BioTek Instruments, Inc.
9
BioVision Inc.
10
Boston Children's Hospital Stem Cell Program
11
Boyalife Group Ltd.
12
California Institute for Regenerative Medicine (CIRM)
13
Cell and Gene Therapy Catapult
14
Cellular Engineering Technologies (CET) Inc.
15
Centre for Commercialization of Regenerative Medicine (CCRM)
16
Cline Scientific AB
17
Coriell Institute for Medical Research
18
Cyfuse Biomedical K.K.
19
DRVision Technologies LLC
20
Elsevier
21
FedEx Services
22
1
Illumina, Inc.
23
Instant Systems
24
Lonza
25
Mill Creek Life Sciences
26
MTI-GlobalStem
27
NACALAI USA., INC.
28
NanoCellect Biomedical, Inc.
29
Nikon Corporation
30
Nippi Incorporated
31
Orla Protein Technologies Ltd
32
PeproTech
33
ReproCELL
34
S-BIO, Sumitomo Bakelite Co., Ltd.
35
Stanford Medicine Inst. for Stem Cell Biology and Regenerative
Medicine
StemBioSys Inc.
36
Takara Bio USA, Inc.
38
Takasago Fluidic Systems
39
The Company of Biologists
40
Thrive Bioscience, Inc.
41
Union Biometrica, Inc.
42
UPM-Kymmene Corporation
43
WiCell
44
Worthington Biochemical Corporation
45
37
2
Single use bioreactor series
For stem cell stirred suspension culture
We are established company of bioreactor in Japan. Our main products are bioreactor and sensor,
process controller. This exhibition, we will show the small scale (30mL, 100mL) of single-use bioreactor
and 6ch magnetic stirrer for stem cell stirred suspension culture.
Features of these products are:



Low share stress agitation
EB formation by gentle mixing
Plastic, gamma radiation sterilized
EB of human iPS
cell
Contact Us
Biott corporation Head office
6-10, Nishigoken-cho, Shinjuku-ku, Tokyo, 162-0812, Japan
Phone: +81-3-3260-0415
Fax: +81-3-3260-0407
Please contact us: https://ab-secure.sslserve.jp/contact_e.php
Home page: http://www.able-biott.co.jp/en/
3
A leading manufacturer of high quality amino acids, Ajinomoto Co., Inc.
Ajinomoto Co., Inc. is the world’s leading manufacturer of amino acids. Throughout our more than 100
years history, we have continually developed innovative manufacturing methods and applications of
amino acids. We are operating in 26 countries and regions now. Today our activities extend beyond the
supply of amino acids to include a wide range of business including amino acids combination foods and
drugs and more. Our global quality assurance system, established through the supply of amino acids
for pharmaceutical applications, puts the customer at the heart of improved product quality. Our
commitment to future expansion of this service ensures our products can be used with confidence.
High performance, high quality Xeno-free media for stem cell culture “StemFit® medium”
At Ajinomoto Co., Inc., we have recently developed StemFit® medium, which enables induced
pluripotent stem (iPS)/embryonic stem (ES) cells to proliferate for long periods. During this process, we
combined the knowledge of Japanese academics about the culturing of iPS cells with the technologies
we use to manufacture amino acids, which we have been continuously developing since the
establishment of our company. Single-cell culturing is an important technique in the field of regenerative
medicine, and StemFit® medium has been shown to perform well during such cultures. StemFit®Basic
is a basic medium that can be used at each stage of the culture process; i.e., during the establishment,
proliferation, and differentiation of iPS/ES cells, which makes it a versatile tool for research purposes.
At present, we can provide samples of StemFit®Basic to researchers in the US for a fee. We will
officially launch this medium in the US in the autumn. We can be contacted at the following e-mail
address.
Medium for iPS/ES cells
StemFit®Basic




High colony forming efficiency
High cost-performance
Week-end free culture
Xeno-free
Contact: [email protected]
Business Strategy & Planning Dept., Aminoscience Division, AJINOMOTO CO., INC.
http://www.ajinomoto.com/en/?scid=av_ot_pc_cojphead_global
4
AllCells Introduces Clinical Grade Products for Further Manufacturing of Allogeneic Cell
Therapies; Fresh Whole Bone Marrow and Leuko Pak products rich in bone marrow stem cells
and immunological cells to be used for further manufacturing of allogeneic cell and tissue
therapies
ALAMEDA, Calif.— AllCells, LLC, (the “company”) announced on May 18, 2016 registration of its
Alameda, CA facilities with the US-FDA enabling the company to immediately provide clinical grade
products to customers developing cell therapies for regenerative medicine and immunotherapy. AllCells
CliniCellsTM Product Line features standard pack sizes of Clinical Grade Fresh Whole Bone Marrow.
In the coming months, AllCells will offer standard pack sizes of Clinical Grade Fresh Leuko Pak
products. Customization of these products will be possible depending upon the customer’s specific
requirements such as donor profile, screening, qualification, and processing criteria.
AllCells CliniCellsTM products are suitable for therapeutic applications and intended for further
processing into allogeneic cell therapies. These clinical grade products serve as a rich source of adult
human bone marrow stem cells such as CD34+ hematopoietic stem and progenitor cells (HSPCs)
capable of differentiating into various mature blood cell types, and mesenchymal stem cells (MSCs)
found in bone marrow which are capable of differentiating into different tissues such as cartilage, bone,
or fat. Clinical Grade Fresh Leuko Pak products are highly enriched leukapheresis derived products
which contain high concentrations of HSPCs, B cells, NK cells, Monocytes, and T-cells for possible
immunotherapy applications.
The company’s quality system complies with US-FDA 21 CFR 1271 regulations. Additionally, AllCells
maintains Biologics and Tissue Bank licenses from California Dept. of Public Health. LeukoLab holds a
clinical laboratory license. Human tissue collection protocols are approved by the company’s Medical
Director and Independent Review Board (IRB) in accordance with federal law. AllCells is prepared to
host customer qualification audits which can be arranged at the convenience of the customer.
AllCells maintains a sizeable database of human donors, and this repository is constantly increasing. For
more information about the availability of clinical grade products, contact us at 1-888-535-3444, or 1510- 521-2600, and [email protected].
About AllCells, LLC
AllCells is a biotechnology company dedicated to providing researchers and biomanufacturing
organizations with high quality primary cells that enable drug discovery, preclinical development, and
manufacturing of cell therapies. Leveraging its expertise in hematology and immunology cell isolations
together with on-site hematologic tissue clinical collection operations, AllCells maintains a large
repository of donor profiles that can be qualified for various biomedical applications. Freshly collected
tissue is immediately processed in contiguous manufacturing facilities to produce purified cell types
having unparalleled quality and consistency. Cells are shipped worldwide, or fresh cells can be
immediately utilized in fee-for-service cell-based assays (“Bioservices”) custom designed according to
customer criteria. For more information, please visit clinical.allcells.com.
5
ALSTEM advances stem cell research and cell reprogramming technologies. We serve scientists and
research teams in biotech and pharmaceutical companies, universities, and related institutions. Our
ideal client is pursuing breakthroughs in cellular function, disease mechanisms, and therapeutic
development, and in doing so faces bottlenecks in capacity and productivity. They need efficiency
boosts to meet goals, either through protocol-enhancing products, or through outsourcing cell line
generation and reprogramming related services. Our quick, responsive, expertise, with low overhead
translates to compelling offers. Our customers get an unsurpassed value ratio of deliverables to cost,
with exceptional turnaround times, and low risk of failure due to our experience and depth.
We don’t over complicate the process of fulfilling customer needs. Our accessible scientists bring an
agile mindset to meeting and exceeding customer expectations. We become an extension of our
customers’ lab, and take a pride of ownership in our contribution toward mutual success.
Among many technical capabilities with respect to induced pluripotent stem cells, ALSTEM can
consistently generate iPSCs from customer supplied PBMCs.
Richard Tait
ALSTEM, LLC
2600 Hilltop Drive, B/C328
Richmond, CA 94806 USA
+1 (510) 708-0096
[email protected]
www.alstembio.com
6
The Maestro™ multi-well microelectrode array platform allows you to “explore life’s circuitry” – in vitro,
functional assessment of electrically active cells (such as neurons and cardiomyocytes) in biologicallyrelevant networks. Perfect for researching the behavior of diseased cells, screening for drugs to treat
that disease, examining potential toxic effects of drug candidates, or characterizing newly created iPS
cells, the Maestro platform delivers an easy-to-use, compact cellular analysis system suitable for any
lab.
Each well of Axion’s MEA plates (12/48/96-wells) contains a planar array of electrodes. Cells (neurons,
in the above diagram and photograph) are cultured on top of the electrodes then plates are placed in
the Maestro system to record activity of the network. Recordings from multiple locations in each well
(64/16/8 electrodes) provides insight into activity of both individual cells on an electrode, but more
importantly, the population of cells as it behaves as a whole.
Is it enough to know your stem cells are the proper lineage through gene expression, FACS, or
Western blots? They may have all the proper characteristics but do they function properly? The
Maestro MEA platform provides a simple, benchtop system delivering powerful insight into electrically
active cell populations.
Contact information:
Catherine Parrish
Product Marketing Manager
[email protected]
980-622-2128
www.axionbio.com
7
Axol Bioscience offers a growing range of primary and induced
pluripotent (iPSC)-derived cells as well as complementary media
and supplements, for robust cell growth in vitro. We specialise in the
use of stem cell technology to manufacture biologically relevant
human cells for disease modelling and drug discovery. Axol’s
current iPSC-derived neural cell range includes highly validated neural stem cells (NSCs), cortical
neurons, dopaminergic neuron precursors and astrocytes from healthy and disease backgrounds
including Alzheimer's and Huntington's diseases. Axol’s cardiovascular range comprises iPSC-derived
cardiomyocytes from healthy donors. All cells are commercially available in large batches, offering
researchers a continuous source from a single donor for consistent and reproducible results across
multiple assays. Axol also provides a complete suite of custom cell sourcing, reprogramming,
differentiation and gene editing services.
New products being launched soon - Find out more at ISSCR 2016
iPSC-Derived Atrial-Like Cardiomyocytes Atrial cardiomyocytes are key for the study of atrial
fibrillation such as irregular heart rate. Axol iPSC-Derived Atrial-Like
Cardiomyocytes express atrial myosin light chain 2 (MLC2a) and have been
derived from the same donor as our highly-validated iPSC-Derived VentricularLike Cardiomyocytes. Axol iPSC-derived cardiomyocytes and fully defined,
serum-free Cardiomyocyte Maintenance Medium Kit offers researchers a
complete portfolio of complementary cell types and culture reagents for disease
modelling and cardiotoxicity testing.
axolGEMs (Genetically Edited Models) Combining the powerful tools of iPSC
gene editing (Horizon Discovery) and our directed differentiation protocols, we have generated a range
of isogenic iPSC-Derived Neural Stem Cells with disease-relevant mutations. This includes cells
carrying the Alzheimer’s disease-associated microtubule-associated protein TAU (MAPT) mutations,
P301L, V337M and R406W and the Parkinson’s disease-associated leucine-rich repeat kinase 2
(LRRK2) mutation, G2019S in both a hetero- and homozygous manner. We also have an isogenic age
and gender matched control available. All axolGEM iPSC-Derived NSCs can be expanded,
differentiated and maintained using our fully defined, Xeno-Free Neural Cell Culture System.
iPSC-Derived Endothelial Colony Forming Cells (ECFCs) Axol iPSC-Derived ECFCs are highlyexpandable and express prototypic markers such as von Willebrand Factor (vWF), CD31, VE-cadherin
and endothelial nitric oxide synthase (eNOS) making them a useful tool for
angiogenesis and endothelial function assays. The vascular endothelium is
continually under fluid shear stress exerted by blood flow and as such
endothelial cells are responsive to pressure and flow. Axol iPSC-Derived
ECFCs respond to fluid shear stress by aligning to physiological unidirectional
shear but fail to do so when exposed to disturbed oscillating shear patterns.
Thus our iPSC-Derived ECFCs exhibit physiologically representative responses
that are of benefit for modelling disease processes.
Contact us: Booth #1612
Sanj Kumar, Chief Business Officer [email protected]
US: 1-800-678-AXOL (2965), International: +44 (0)1223 751 051 www.axolbio.com
8
BioTek Showcases New Technologies for Live and Fixed Cell Assays
BioTek® is recognized worldwide for designing and manufacturing high-value, customer driven
microplate-based instrumentation used to aid in the advancement of life science research, facilitate the
drug discovery process and to enable cost-effective quantification of disease relevant molecules in the
clinic. BioTek’s comprehensive product line includes automated widefield digital microscopy systems,
multi-mode and single mode microplate detection systems for absorbance, fluorescence and
luminescence measurements. BioTek’s liquid handling products include microplate washers,
dispensers and pipetting systems. Automated incubators, microplate stackers, powerful data and image
analysis software, and myriad accessory options provide the complete solution for laboratories around
the world.
At ISSCR 2016 booth #1310, BioTek will present its new Lionheart™ FX Automated Live Cell Imager
with Augmented Microscopy™ which is optimized for live cell applications, with automated image
capture, analysis, annotation and video production. This fully-integrated digital microscopy system
includes fluorescence, brightfield, color brightfield and phase contrast up to 100x magnification.
Temperature, gas and humidity control create an ideal environment for a wide variety of cell-based
studies.
Lionheart™ FX Automated Live Cell Imager with Augmented Microscopy™.
www.biotek.com
9
BioVision Inc., is a privately held Life Science company, we develop and offer a wide variety of
products including assay kits, antibodies, recombinant proteins, enzymes, and other innovative
research tools for studying Stem Cell Biology , Apoptosis, Metabolism, Cell Proliferation, Cellular
Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Gene Regulation,
Signal Transduction and many more disease areas. Our prime focus is to supply high quality products
and assuring customer satisfaction by providing affordable and innovative research tools.
We continue to expand our stem cell portfolio in Antibodies, Assay Kits, Cytokines and Growth Factors,
stem cell fate modulators, Neuronal Transdifferentiation Modulators, DiscoveryPak stem cell fate
modulators sets, StemBoost reprogramming cocktail sets, Molecular Biology research tools and many
more. Our products are used in over 70 countries targeting different areas of research.
Please visit our website to view all these products. http://www.biovision.com/stem-cell-research-tools1060/
Contact information:
Archana G
[email protected];
[email protected]
BioVision Inc., is a privately held Life Science company, we develop and offer a wide variety of
products including assay kits, antibodies, recombinant proteins, enzymes, and other innovative
research tools for studying Stem Cell Biology , Apoptosis, Metabolism, Cell Proliferation, Cellular
Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Gene Regulation,
Signal Transduction and many more disease areas. Our prime focus is to supply high quality products
and assuring customer satisfaction by providing affordable and innovative research tools.
10
Stem cell research holds great promise for advances in science, medicine, and the lives of children and
adults living with serious and currently incurable diseases. The Stem Cell program at Harvard-affiliated
Boston Children's Hospital brings together premier physicians from many backgrounds and specialties
to form one of the top stem cell research teams in the world.
Encompassing six primary labs with more than 80 scientists, plus 45 associated laboratories
with over 300 scientists, the Stem Cell Program has delivered many of the field's most
important breakthroughs. Two stem cell drugs are now in clinical trials. One boosts blood
stem cell production for leukemia and lymphoma patients, and the other represses stem cell
genes that turn ordinary skin cells into melanoma. A third, which regenerates muscle using
cell therapy, will enter clinical trials in the next two years.
Our researchers have, for the first time, visualized the origins of cancer from the first
affected cell and watched its spread in a live animal. The work of Drs. Leonard Zon and
Charles Kaufman, which was published in the January 29, 2016 issue of Science, could
change the way scientists understand melanoma and other cancers. It could lead to new,
early treatments before cancer has taken hold.
The Stem Cell Program and its affiliated scientists are also creating induced pluripotent stem
cells (iPSCs) from patients with multiple disorders and using them to generate specialized cells
that model their conditions in miniature and that can be used for screening potential drugs
For more information, please reference the Stem Cell Program website at
http://stemcell.childrenshospital.org/ or contact Dr. Leonard Zon at 617-919-2068.
11
Boyalife Group
Advancing Frontier in Biomedical Research
Boyalife Group (www.boyalifegroup.com), along with its affiliated companies, previously known as the
International Consortium of Stem Cell Research (INCOSC), was founded in July 2009 in China as an
industrial-research alliance among top research institutes for stem cell and regenerative medicine.
Boyalife Group is actively engaged in stem cell technologies (SH: 600165), regenerative medicine (Nasdaq:
KOOL), genomics and cloning, cancer immune therapies, disease mechanistic studies and innovative drug
discovery.
Leading Brand in Healthcare in China
In 2012, Boyalife Group won the prestigious “2012 CCTV China Brand Award”, emerging as a leading
brand in healthcare in China.
In 2015, Boyalife Stem Cell Bank get listed in Shanghai stock exchange (SH:600165).
World’s Largest Cloning Factory
In 2015, Boyalife Genomics Ltd. signed with Tianjin Municipal Government to build the world’s largest
cloning factory.
First Global Award For Stem Cell and Regenerative Medicine
In 2015, Boyalife and Science magazine jointly launch a global award in Stem Cell and Regenerative
Medicine, namely the “Boyalife, Science& Science Translational Medicine Award in Stem Cell and
Regenerative Medicine”, to be awarded to individuals who have made significant contributions to the
field.
Investment Hold Cesca Therapeutics Inc. (NASDAQ: KOOL)
In 2016, Boyalife Group acquires Cesca Therapeutics Inc. (NASDAQ: KOOL) —— a leader in automated
blood and bone marrow processing systems.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and
commercialization of cellular therapies and delivery systems for use in regenerative medicine.
www.boyalifegroup.com
Our Booth Number:1227
Contact:
Emma Li: (+86) 150 6155 1010
Nora Qiao:[email protected]
Dina Weng:[email protected]
12
Contact: Kevin McCormack [email protected] 510-340-9147
Or Don Gibbons [email protected] 510-340-9160
California Institute for Regenerative Medicine. CIRM—California’s stem cell agency created by a $3
billion voter referendum—made an abrupt shift in the way it supports research in January 2015. The
radical change from its first 10 years blazed a completely new trail for government funding of research.
The time from grant application to money in hand dropped from nearly two years to less than 120 days.
And the grants are not based on a set time frame. Funds are distributed based on pre-set milestones
and grantees are encouraged to complete their projects as quickly as possible.
The agency becomes an active partner in projects, setting up an individual Clinical Advisory Panel for
all clinical awards. Each panel has at least one CIRM scientist, one outside expert and one patient
advocate who is encouraged to be active in clinical trial design and review at quarterly meetings.
Under CIRM2.0 clinical awards are accepted on the last business day of every month. Applications
undergo financial review to ensure their budget is appropriate and a scientific review by a panel of 15
independent experts. If recommended for funding they have to have their project up and running in 45
days after the award. This encourages teams to wait until they are really ready to start work before
applying. Applicants not recommended by the reviewers are given advise and can reapply with
improved applications any month.
CIRM encourages teams anywhere in the world to apply for funding. For groups outside of California,
the agency can fund significant portions of clinical trial sites in California, or pre-clinical contract work
performed in California.
CIRM currently funds active clinical trials:
HIV/AIDS (x2)
Retinitis pigmentosa
Solid Tumors (x2)
AIDS-related lymphoma
Heart Disease (x2)
Leukemia
Chronic granulomatous
disease
Diabetes
Glioblastoma
Sickle Cell Anemia
Spinal cord injury
Age related macular
degeneration
13
The Cell and Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance
the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale
commercialisation. With more than 100 employees focusing on cell and gene therapy technologies, we work with
our partners in academia and industry to ensure these life-changing therapies can be developed for use in health
services throughout the world. We offer leading-edge capability, technology and innovation to enable companies
to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health
economics and market access expertise. We aim to make the UK the most compelling and logical choice for UK
and international partners to develop and commercialise these advanced therapies. Regenerative medicine is one
of the UK government’s “eight great technologies” that support UK science strengths and business capabilities.
The Cell and Gene Therapy Catapult works with Innovate UK. For more information go to ct.catapult.org.uk.
14
Company Description
CET specializes in stem cell research, tissue engineering and cancer biology. We provide media and
stem cells obtained from human non-embryonic sources such as adipose tissue, bone marrow,
wharton’s jelly, umbilical cord blood, and placentas. In addition, CET is a leading provider of induced
pluripotent (IPS) stem cells derived from normal human volunteers and patients with various clinical
conditions. We also provide custom IPS reprogramming services. Our engineering focus is on
preclinical drug discovery and high throughput drug screening. CET's cancer biology focus is on the
isolation and culture of solid tumors from cancers of the breast, colon, kidney, lung and prostate.
Specialties
Stem Cell Research, Tissue Engineering, Cancer Biology, Expansion Media, Induced Pluripotent Stem
Cells, Custom Reprogramming Services, Human Mesenchymal Stem Cells, Bone Marrow Derived
Cells, Adipose Derived Cells, Mouse Cells, Differentiation Media
Media Contact
Please contact Ms. Sara Ternes for all media inquiries at: (319) 210-7554 or via email at:
[email protected] ; www.celleng-tech.com
15
CCRM is a unique, not-for-profit group that is solely focused on developing and commercializing
regenerative medicine technologies. We are leveraging our network of academics and industry partners
to advance our most promising technologies to the market and meet the needs of patients of the future.
CCRM sources and evaluates intellectual property from around the globe, offers various consulting
services, conducts development projects with partners, and establishes new companies built around
strategic bundles of intellectual property. CCRM has a fully resourced, 6,000 square foot development
facility used to both evaluate and advance technologies and 40,000 square feet in development for
advanced cell manufacturing.
Introducing BridGE@CCRM
A result of the collaborative efforts of CCRM, GE Healthcare and the Government of Canada,
BridGE@CCRM is building on the knowledge and skillsets of GE and CCRM to develop the next
generation of solutions for effective manufacturing of cell and gene therapy products, to ultimately make
these treatments more accessible to patients.
BridGE@CCRM can develop the tools, processes and advanced technologies necessary for efficient
and reliable manufacturing of cellular therapies.
Our contract process development services include:
 Process closure and automation
 Scale-up/Scale-out
 Cost reduction
 Process optimization
 Media optimization/screening
 Process and manufacturing operations modelling
BridGE@CCRM is looking to partner with select companies that have unique technologies that can be
integrated into cell manufacturing workflows.
GMP Facility
BridGE will be co-located with a cell therapy GMP facility being built in partnership with University
Health Network (UHN), to be operated by CCRM.
For more information, please contact:
Stacey Johnson
Director, Communications
647-309-1830
[email protected]
www.ccrm.ca
16
Cline Scientific is a Swedish publicly traded
company. It was founded 2012 and is based in
Gothenburg. Cline’s products and services are
based on patented nano-technology.
Products and services – Small Surfaces for Cell Control
Cline Scientific is the only provider in the world of surface Nanogradients. These are today used in two
main areas: stem cell differentiation and cell migration, for the development of stem cell therapies and
within cancer research.
Ultimate Cell Control through Molecular Precision
A gradient pattern of biomolecules (e.g. growth factor, laminin, etc.) on Cline’s unique surfaces can be
used to mimic in-vivo responses in-vitro, to precisely control cell development. The products can be
customized to meet your needs.
Graphics showing how the Cline Nano Gradient can be used for optimal stem cell differentiation – Visit
our booth #1731 to learn more!
One Surface
Replaces Thousands of Experiments
Cline’s products are consumables that are designed to fit available laboratory equipment, such as
microscopes and cell culture plastics. Apply your favorite molecules, add your cells, and get results
faster than ever!
Contact information
www.clinescientific.com
phone: +46 31 387 55 55
e-mail: [email protected]
17
Coriell Institute is a leading biorepository delivering a diverse range of unique biospecimen. The
Institute is committed to the highest standard in cell line quality services, as well as unlocking the
promise of induced pluripotent stem cells and their role in disease research and drug discovery. For
more information, visit catalog.coriell.org.
Service Highlights


Coriell houses the world’s largest, publicly available collection of human induced pluripotent stem
cells (hiPSC) in partnership with the California Institute for Regenerative Medicine (CIRM)
The hiPSC collection represents a diverse range of diseases (Alzheimer’s, autism spectrum
disorders, cerebral palsy, glaucoma) and includes comprehensive clinical data
On the web:
www.coriell.org – Education and Information
catalog.coriell.org – Coriell Biomaterial Services
Contact:
Matthew Chimento
Associate Manager, Communications
(856) 757-9710
[email protected]
18
Cyfuse Biomedical K.K. is a Japanese biotech company that has created a unique 3D bioprinter called
the engineering.Regenova, which uses the Kenzan method. The Regenova is the only commercially
available 3D bioprinter that is able to print without any scaffold materials. There are four machines in
North America and 10 machines in Japan, and these machines are actively used for research including
stem research, regenerative medicine and tissue
The Regenova has succeeded in printing a blood vessel that can be handled with surgical instruments.
Currently, there are also several ongoing applications: a neural model, a liver model for drug
development, heart tissue, a cancer invasion model and so on.
If you have any questions, please feel free to contact Joe Ono: [email protected].
For more details, please visit our website: http://www.cyfusebio.com/en/regenova.html.
19
Image Analysis is No Longer Just for Experts
SVCell RS is a revolutionary image analysis software that gives you expert results. The
software comes with many image analysis workflows called recipes covering a broad range
of applications from subcellular particles to whole cells - no image processing experience
required. With SVCell RS, get from image to quality results quickly and easily.
Feature Highlights
Overview
SVCell RS combines powerful image analysis
solutions, impressive visualizations, and
intuitive editing tools in a single software
package to help you analyze your images
quickly and easily. There is no complicated
toolbox to learn and no codes to compile simply load your image, select a recipe to run,
and get results.
Recipe-driven image analysis
SVCell RS technologies draw on decades of
image processing experience. With over 40
patents issued and over $7 million in NIH
funding, you can leave the image analysis to
us and spend more time on the science.
Smart editing
Recipes are image analysis workflows that
combine image enhancement, detection,
and measurement.
Frame-by-frame analysis
Recipe processes and updates the results
one frame at a time. View, pause, update.
Your edits guide subsequent automated
processing and results update.
Linked data visualizations
Image, chart and data table are all connected
Download a free trial today at www.svcell.com/download-trial
for visualization and analysis.
https://www.svcell.com
[email protected]
(855) 423-5577
20
About Cell Press
Cell Press is committed to improving scientific communication through
the publication of exciting research and reviews. Our journals deliver the
highest possible intellectual rigor, promote community trust, and are
widely disseminated. Cell Press primary research journals include the
flagship journal Cell, Cell Stem Cell, Current Biology, Neuron, Cell
Systems, and the open-access Cell Reports. Our portfolio also includes
a suite of 15 Trends journals that review key themes across the
sciences. Cell Press publishes four journals on behalf of learned
societies, including the International Society for Stem Cell Research’s
open-access journal Stem Cell Reports. For more information, please
visit www.cell.com.
Recent News Headlines from Cell Press Journals
Cell: Zika is test case for brain organoid mini-reactors
The Zika virus epidemic comes at a time when new stem cell techniques for
studying the brain are being refined and tested. In Cell, researchers in the U.S.
unveil brain-region-specific organoids that show in three dimensions how the
virus affects the human brain. The organoid data support that Zika prefers to
infect neural stem cells and that the extent of damage differs depending on time
of infection.
Cell Stem Cell: Stem cell technique makes sperm in a dish
Scientists in China have succeeded in creating functioning sperm from mice in
the laboratory. To accomplish this feat, the researchers coaxed mouse
embryonic stem cells to turn into functional sperm-like cells, which were then
injected into egg cells to produce fertile mouse offspring. The work provides a
platform for generating sperm cells that could one day be used to treat male
infertility in humans.
Stem Cell Reports: 3D “mini-retinas” grown from mouse and human
stem cells
Stem cell science has progressed so that researchers can now share recipes
for making human retinas—the part of the eye that is sensitive to light. The first
protocols enabled the generation of retinal cells in laboratory plates and more
recently as complex tissue in tiny eye-like cups. Researchers in Germany now
have another efficient way to make 3D retina organoids, which mimic the
organ's tissue organization, from mouse or human stem cells. Their 3D "miniretinas” offer new perspectives on retina growth, injury, and repair.
To receive Cell Press embargoed media packages, please contact
[email protected] or call 617-335-6270
21
FedEx provides customers and businesses worldwide with a broad portfolio of transportation, ecommerce and business services. With annual revenues of $49 billion, the company offers integrated
business applications through operating companies competing collectively and managed
collaboratively, under the respected FedEx brand. Consistently ranked among the world’s most
admired and trusted employers, FedEx inspires its more than 340,000 team members to remain
“absolutely, positively” focused on safety, the highest ethical and professional standards and the needs
of their customers and communities. For more information, please visit www.fedex.com
22
About Illumina
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems
for large-scale analysis of genetic variation and function. These systems are enabling studies that were
not even imaginable just a few years ago, and moving us closer to the realization of personalized
medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are
not only innovative, but also flexible, and scalable, with industry-leading support and service.
Leading-edge products and services
Illumina has developed a comprehensive line of products that address the scale of experimentation and
breadth of functional analysis to advance disease research, drug development, and the development of
molecular tests. Our broad portfolio of leading-edge sequencing and array-based solutions address a
range of genomic complexity and throughput, enabling researchers to select the best solution for their
scientific challenge.
About DNA and RNA sequencing
Illumina next-generation sequencing (NGS) technology can be
used to sequence the DNA from any organism, providing
valuable information in response to almost any biological
question. A highly scalable technology, DNA sequencing can be
applied to small, targeted regions or the entire genome through
a variety of methods, enabling researchers to investigate and better understand health and disease.
RNA sequencing (RNA-Seq) is revolutionizing the study of the transcriptome. It is providing visibility to
previously undetected changes occurring in disease states, in response to therapeutics, under different
environmental conditions and across a broad range of other study designs. RNA-Seq allows
researchers to detect both known and novel features in a single assay, enabling the detection of
transcript isoforms, gene fusions, single nucleotide variants, allele-specific gene expression and other
features without the limitation of prior knowledge.
Learn more at: www.illumina.com
Subscribe to Illumina updates at: www.illumina.com/newscenter
Email Illumina public relations at: [email protected]
Be social!
@illumina
Illuminainc
Illumina
23
“Companies come to us because the packaging they require does
not exist on the market and they need us to create it.”
President, Tara Ramsey.
Instant Systems is the Industry leader in custom, high-performance, film-based packaging. Specializing
in application specific solutions for cryopreservation, cellular therapy, bioprocessing and industrial use,
Instant Systems designs packaging that improves a product’s reputation by reducing failures and loss.
“Companies come to us because the packaging they require does not exist on the market and they
need us to create it.” says company president Tara Ramsey. “From concept to full-scale production, our
team helps our clients solve their packaging issues. By working with us, clients gain instant access to a
team of systems engineers and packaging experts.”
Instant Systems’ rapid development program was created to assist clients in moving their products from
concept to reality in a short period of time. “Once we understand the project, our engineers produce
prototypes quickly allowing our customers to test their ideas in just days.” says Vice-President of
Research and Development, Kimber Burley. “Our engineers work tirelessly to expose all potential
threats to the product and then design the correct application specific solution required to prevent
failures”.
Founded in 2005, Instant Systems has grown from a small single product specialty firm to a company
with capabilities to produce high-performance solutions for any industry. From ultra-low temperature
applications to ideal biological environments, Instant Systems’ engineers thrive on creating viable
solutions for extremely challenging applications.
If you have a product, research project and/or a production program that requires specialized
packaging, contact Instant Systems at 800.706.5808 or [email protected].
24
Lonza – Building Bridges from Stem Cell Research to Therapy
Lonza is committed to supporting your stem cell research by providing primary cells, media and culturing
solutions as well as transfection tools. If you’re ready for the clinic, our cell therapy services might be the answer
you need for development, manufacturing and testing of your stem cell-based therapeutics.
Visit us at booth 1411 to discover how our cell and transfection research products partnered with clinical cell
therapy services can help you build bridges from stem cell research to therapy.
Cells and Media
Whether you need purified adult stem/progenitor cells or iPSC tools, Lonza has the optimal cell and media
solution you’re looking for. If you don’t see the stem cell type you need in our catalog, we can likely isolate cells
for you through our Cells on Demand Service.
3D Cell Culture Solutions
The RAFT™ System has been designed with usability in mind, with simple easy-to-follow protocols that allow
researchers to set up 3D cell cultures in under an hour. The novel RAFT™ System uses a unique method that
allows formation of robust, high-density collagen scaffolds with cells embedded. The resulting RAFT™ 3D
cultures are easy to handle for downstream assays, enable long-term culture maintenance and allow formation
of multilayer 3D models.
Live Cell Monitoring
With our new CytoSMART™ System, live cell imaging has become easy and affordable. It is sized and priced for
virtually any lab and budget. Document and record your cell culture for a multitude of purposes and at any given
time and place by using the CytoSMART™ Connect Cloud Service.
Transfection
Lonza’s Large Volume 4D-Nucleofector™ LV Unit can transfect up to 1x109 cells without the need for reoptimization from your smaller-scale format. With this new addition to the established 4D-Nucleofector™
System, small- and large-scale transfection applications are seamless!
Clinical Cell Therapy Services
We partner with clients to develop client-specific custom protocols to meet each unique business need from raw
material requirements and process flow to storage and distribution.
Please visit www.lonza.com/stem for additional information or contact our scientific support team at
[email protected].
25
Overview
We offer the best platelet lysate available! Stem cells are changing medicine, and we want
to be the platelet lysate supplier of choice. PLTMax® has the proven track record of successful clinical
use that trials and researchers demand.
PLTMax® is the original human platelet based cell culture supplement. It is derived from human
platelets and offers unparalleled cell growth for stem cells. Donor units are pooled in large batch sizes
and manufactured according to our proprietary methods to produce a consistent product. PLTMax® is a
commercially available, consistent and proven alternative to lab-based platelet lysate.
PLTMax® is available in both clinical and research grade in 100mL and 500mL sizes. Clinical grade is
manufactured under GMP conditions for use in GMP compliant cell culture SOPs. Research grade is
manufactured to meet the needs of research and development. Manufacturing methods are consistent
with our clinical grade assuring you an easy transition to clinical manufacturing as you move your
protocol to the clinic.
PLTMax® has been a critical ingredient in Phase I, Phase II and Phase III trials in North America,
Europe, South America, Middle East, Asia and Australia. It has been used to grow cells for hundreds of
patient samples, and used to culture bone marrow and adipose derived MSC and other primary cell
cultures. The first GMP platelet lysate on the market, the best on the market and a master file with the
FDA to accelerate application. Our quality and experience mean more growth for the customer!
From bench to bedside, we are with our customers all the way! Mill Creek Life Sciences is dedicated to
meeting ALL quality requirements. GMP media supplements are our only business so PLTMax® is
available when customers need it, as is our support. Visit our website, request a sample and see the
PLTMax® difference!
Website
www.millcreekls.com
Contact Information
Bill Mirsch, CEO ([email protected])
Vanesa Alonso Camino, Staff Scientist ([email protected])
Jeff Nielsen, Office Manager ([email protected])
Phone: 507-287-6257
Fax: 507-289-2066
26
About MTI-GlobalStem
MTI-GlobalStem is a leading supplier of cutting-edge tools and reagents for the life sciences.
GlobalStem was formed in 2006 and acquired by Molecular Transfer, Inc. (MTI) in 2009. The formation
of MTI-GlobalStem in 2015 merged MTI’s groundbreaking technologies in the areas of transfection and
high-efficiency gene delivery with GlobalStem’s expertise in stem cell and neurobiology.
MTI-GlobalStem has an active research program that utilizes expertise in high-efficiency gene delivery,
neuroscience and stem cell biology to develop and
supply scientists with the necessary tools and
reagents to help advance new discoveries and
developments in the life sciences. Utilizing our
intellectual property and know-how, and a specialized
team of highly skilled and experienced scientists, we
are leading the way with next-generation transfection reagents for a
solution-focused approach to stem cell and neurobiology
applications, and we are filling the gap with high-quality primary
and iPSC-derived neural cells, stem cells and supporting feeder
cells, and optimized cell culture media and supplements.
Contact Information:
MTI-GlobalStem
200 Perry Parkway, Suite 1
Gaithersburg. MD 20877
www.mti-globalstem.com
[email protected]
Phone 301-545-0238 / 888-545-0238
Fax 301-424-1989
27
About Nacalai USA, Inc.
Nacalai USA, Inc., a wholly-owned subsidiary of Nacalai Tesque, Inc., Kyoto Japan., was founded in
January 2005 in San Diego, California to bridge between the United States and Japan in the scientific
research community. Nacalai USA strives to bring the most innovative and stringently quality-controlled
biochemicals and research tools from Japan into the United States market.
New Products:
Cardiomyocyte Differentiation Medium: Production of high quality cardiomyocytes
Cardiomyocyte Differentiation Medium is specifically optimized for
differentiation of human iPS cells to contractive cardiomyocytes.
cellnest: Recombinant peptide based on human collagen type I
Xeno-free recombinant peptide has an increased arginine-glycine-aspartate (RGD) sequences with
high cellular adhesion.
EZSPHERE®: Cell culture ware for spheroid formation
EZSPHERE® has a lot of evenly designed micro wells on the surface. Inoculated cells drop into the
micro wells and form uniformly sized Spheroids.
Contact us:
Nacalai USA, Inc.
10225 Barnes Canyon Rd., Suite A103
San Diego, CA 92121, USA
Phone: 858-404-0403
28
e-mail: [email protected]
www.nacalaiusa.com
NanoCellect's mission is to facilitate biomedical breakthroughs by making cell analysis and sorting
technology more affordable and easier to use. Our microfluidic flow cytometry platforms enable
biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic
research.
Our WOLF Cell Sorter uses gentle microfluidics and five optical parameters for true two-way sorting.
Because it creates no biohazardous aerosols, it can be used at the bench. And because it is small, it
fits in the hood. We make sorting…
safe
simple
sterile
small…
Please contact us at:
NanoCellect Biomedical, Inc.
7770 Regents Road 113390
San Diego CA 92122
877-745-SORT (7678)
[email protected]
www.nanocellect.com
29
Nikon has provided microscope systems for almost 100 years. For the ISSCR meeting, Nikon introduces
following systems specially design for all the stem cell needs:
1. Eclipse Ti – Inverted Research Microscope. Scientists have overcome many live cell imaging
challenges using advanced techniques such as TIRF, confocal, FRET, photoactivation and
microinjection. At the center of it all is the Eclipse Ti, a powerful inverted microscope featuring Nikon
CFI60 optics and the Perfect Focus System. Offering improved system speed, increased flexibility
and efficient multi-mode microscope it is an ideal system for high-end research and live cell imaging.
New high content software tools will also be featured.
2. Eclipse Ts2/Ts2R – Inverted Microscope. Nikon’s new microscope provides an easy operation and
clear images for your advanced research.
3. SMZ25 – Stereomicroscope. Nikon’s new SMZ25 research stereomicroscope combines macro and
micro imaging in one instrument for convenient viewing and manipulation of single cells to whole
organisms. Using Nikon’s Perfect Zoom System, the SMZ25 achieves the world’s first 25:1 zoom and
high NA for superior resolution.
4. BioStudio - Compact Automated Microscope. Automated Microscope allows users to use it in a
culture incubator, isolator and resists hydrogen peroxide gas (VHP).
5. BioStation CT platform – Stem Cell Screening System. BioStation CT platform is an integrated cell
culture incubator, microscope and digital imaging system with advanced analysis software. The system
is ideal for stem cell research. Nikon will show some applications including the disease modeling,
protocol standardization and Label-free analysis technique.
Innovation showcase provided by Nikon
Developing a live cell system for visualizing neuronal degeneration.
Speaker : Professor Lee L. Rubin, PhD
(Director of HSCI’s Therapeutic Screening Center, Professor in Harvard University)
Date : Thursday, 23 June
Time : 11:30 a.m. – 12:30 p.m.
VENUE: Level 2, Rooms 2009/2011
(Lunch provided !)
Contact Information:
Yasujiro Kiyota
Manager Stem Cell Business Development Section
Microscope Solutions Business Unit
NIKON CORPORATION
Email: [email protected]
Nikon Corporation booth number 1318.
30
Nippi, Inc., Tokyo, Japan
Nippi's iMatrix-511 is the best culture substrate for iPS/ES cells.
Efficient 1:100 split ratio for "single-cell passaging" of iPS cells.
Contact:
Nippi, Inc. [email protected] Booth#1713
High-quality low endotoxin medical grade gelatin and various types of collagens are also available.
31
Immobilised proteins are essential in all aspects of Life Sciences research and development. Orla
Protein Technologies has a proven platform for immobilising proteins and functionalising surfaces for
applications. For our customers, we engineer proteins and develop customised protein surfaces with
high orientation and function resulting in better performance and reproducibility.
Products and Services
Orla gives researchers, developers and manufacturers unprecedented control of surface presentation
of proteins through proprietary technology that radically simplifies the production of immobilised protein
surfaces. OrlaSURF dramatically improves functionality, utility, and suitability for large-scale
manufacture, thus enabling our customers to improve their products and processes.
Our business model is based around providing customers and partners with:
1. Technology Access and Intellectual Property
2. Contract R&D and Services – protein design and
manufacture for a wide variety of applications, biosurface development and protein analytical services.
3. Off-the-shelf Products – functionalised well plates for
culture applications, protein kits for analytical surfaces,
proteins and surfaces for assay development, and
specialist recombinant proteins.
cell
Next Generation of Cell Culture Surfaces
Immobilised proteins are key to support the growth and development of cells in culture. Current
methods of adsorption and chemical coupling are non-specific and lead to inconsistent results.
We understand the importance of animal-free natural-like environments for cells. With our ability to
create highly defined mixed protein surfaces and to include ECM motifs and growth factors we can
create the environment meeting the exact needs of a specific cell type.
At Orla, we help partners find their optimal protein surface and manufacture reproducibly. OrlaExplorer
plates are an easy and efficient way to screen for the best protein surface combination for a given cell
type. Subsequently, scalability and high reproducibility enable efficient commercial manufacture.
Contact
Biomedicine West Wing, International Centre for Life
Newcastle upon Tyne, NE1 4E, UK
T: +44 191 231 3127
E: [email protected]
W: www.orlaproteins.com
32
Supporting Life Science Research since 1988, PeproTech is the trusted source for the developing and
manufacturing of high quality cytokine products for the life-science and cell therapy market.
Over the past 28 years the company has grown into a global enterprise with state-of-the-art
manufacturing facilities in the US, and offices around the world.
With over 2,000 products PeproTech has developed and refined innovated protocols to ensure quality,
reliability and consistency.
Our mission is to provide the highest quality products and premium support that address the needs and
demands of today's scientists and researchers.
We pride ourselves on being a trusted partner within the scientific community.
•Comprehensive line of Cytokines and Antibodies
•GMP Cytokines for Cell, Gene and Tissue Therapy
•Animal-Free Cytokines
•ELISA Development Kits
•Media Kits / Supplements
33
ReproCELL, and its group companies are dedicated
to providing researchers with single source bench-tobedside solutions for the advancement of stem cell
and human tissue research in drug discovery and
regenerative medicine. The ReproCELL brands
include:
AMERICAS—HUMAN TISSUE
o
9000 Virginia Manor Road, Suite 207
Beltsville, MD 20705, USA
T: (301) 470-3362
[email protected] | www.bioserve.com
o
o
Extensive biorepository of human
tissue samples
Network of clinical sites for
prospective sample collection
Molecular services
AMERICAS—REAGENTS
51 Moulton Street
Cambridge, MA 02138, USA
T: (617) 245-0000
[email protected] | www.stemgent.com
o
o
o
RNA Reprogramming systems and
services
Reagents for pluripotent cell culture
and differentiation
Extensive portfolio of small
molecules
ASIA PACIFIC
o
KDX Shin-yokohama381 Bldg9F,3-8-11
Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa
222-0033, Japan
T: +81 45 475 3887
[email protected] | www.reprocell.com/en
o
Global provider of differentiated cell
types; iPSC-derived hepatocytes,
cardiomyocytes, and neurons
Extensive portfolio of embryonic
and induced pluripotent stem cell
culture reagents
EUROPE
o
NETPark Incubator,Thomas Wright Way, Sedgefield,
Co. Durham
TS21 3FD, UNITED KINGDOM
T: +44 (0)1740 625 266
[email protected] | www.reinnervate.com
o
3D cell culture technology creating
an in vivo like cell environment
Protocols for stem cell, oncology,
and other tissue research
applications
AMERICAS & EUROPE HUMAN
TISSUE ASSAYS
o
Weipers Centre, Garscube Estate
Bearsden Road, Glasgow G61 1QH,
UNITED KINGDOM
T: +44 (0)141 330 3831
[email protected] | www.biopta.com
o
Experts in human tissue contract
research services for drug
development
Predictive safety, efficacy and
ADME assays in human and animal
tissues
34
S-BIO, Sumitomo Bakelite Co., Ltd.
S-BIO is a division of Sumitomo Bakelite Co., Ltd. (a pioneer in plastics with products used for a wideranging applications such as IT components and material, high performance plastics and quality-of-life
product). S-BIO in US operates as a part of Vaupell Holdings Inc., a group company of Sumitomo
Bakelite Co., Ltd. S-BIO’s main product and services fall into two categories: glycan analysis related
services and products, and high performance labware for cell culture applications.
HIGH PERFORMANCE LABWARE FOR CELL CULTURE APPLICATIONS
S-BIO offers a line of cell culture labware, specializing in 3D cell culture, with demonstrated high
performance. For more than 20 years S-BIO has been leveraging its knowledge of plastics and
coatings to provided extremely low adhesion cell culture labware based on out PrimeSurface
hydrophilic coating process. PrimeSurface plates are available for spheroid formation which is needed
in Stem Cell growth and differentiation. PrimeSurface plates are available in 96 and 384 well format
with a broad range of well bottom (U,V,M) formats to suit spheroid formation of the different cell lines.
For more information, please visit http://s-bio.com/product-category/products/3d-cell-culture/
GLYCAN ANALYSIS PRODUCTS AND SERVICES
S-BIO offers products and high throughput analysis services and kits based our BlotGlyco® polymer
beads used in glycan purification.
Services and Products
S-BIO specializes in the rapid and efficient analysis of both N-linked and O-linked glycans in stem cell
differentiation. Our proprietary GlycanMap® Services that combines BlotGlyco® bead-based glycan
purification in a fully automated sample processing system with high throughput MALDI-TOF mass
spectrometry to generate rapid, reproducible glycan profiles which are qualitative and quantitative. SBIO’s services provide a new solution to accelerate your research in stem cell differentiation. S-BIO
provides several products for glycan analysis such as glycan beads, glycan arrays and customized
glycan plates, For a full list of glycan products, please visit http://s-bio.com/productcategory/products/glycan-analysis/
Contact: S-BIO, Sumitomo Bakelite Co., Ltd., 20 Executive Dr, Hudson, NH 03051.
Email:[email protected], Tel: (603) 425 9697 www.s-bio.com
35
THE FIRST
CHILDREN’S
BOOK
ABOUT STEM
CELLS
*Discounts on bulk
orders available at
ISSCR.
*available on Amazon
About Us
Stanford Medicine Institute for Stem Cell Biology and Regenerative Medicine was established
in 2002 to build on Stanford’s leadership in stem cell science and to set the foundations for the
creation of a new field of science: regenerative medicine. The Institute is devoted to exploring
how stem cells are created, the mechanisms by which they are regulated and how they
devolve into specialized cells.
Stem Cells are Everywhere! is a children's book written to inspire curiosity about how plants
and animals grow and rebuild after injury. How does our body continuously make blood?
Keeping the subject simple enough for young readers, a pioneer of stem cell research explains
cells, tissues, normal growth, what can go wrong, and how to fix it.
Irving L. Weissman, MD is the Director of the Stanford Medicine Institute
for Stem Cell Biology and Regenerative Medicine. All author royalties go to support science
education programs through Stanford Medicine Institute for Stem Cell Biology and
Regenerative Medicine.
http://med.stanford.edu/stemcell.html
36
Enabling Innovative Regenerative Medicine Solutions: StemBioSys is committed to enhancing the
quality and economics of isolating, growing and delivering stem cells through our novel High Performance
Micro Environment (HPME®) technology. Our patented bone marrow HPME (BM-HPME®) creates a
natural, protein based environment that allows a variety of stem cells to replicate more rapidly and with
greater preservation of stem cell potency and potential.
About HPME®
Stem cells have emerged as the future of health care but there are a number of unmet needs which
must be addressed before widespread clinical and therapeutic applications become a reality.
StemBioSys’ HPME® platform technologies offer several potential solutions.
Our novel technology platform is an advanced stem cell culture system that replicates the 3dimensional “home” in which stem cells naturally reside and proliferate. Our unique technology enables
users to isolate and grow stem cells from a variety of sources including but not limited to adipose, bone
marrow and umbilical cord blood/tissue.
BM-HPME® Is Ready-to-Use
For the research market, the Bone Marrow – HPME® is already attached to the culture vessel, no
reconstitution of powders or fluids and coating of dishes is required. Each lot is quality tested to help
ensure consistency.
BM-HPME® Is Available in Multiple Sizes
StemBioSys offers a variety of aseptically prepared pre-coated cell culture plates and flasks and are
suited for a broad range of applications. BM-HPME® is available in 6 well plates, 100 mm dishes, and
the T-75 and T-150 flask formats.
To learn more about BM-HPME® visit us at www.stembiosys.com or call us at 210-877-9323.
StemBioSys, Inc.
3463 Magic Drive, Ste. 110
San Antonio, Texas, 78229
*HPME® and BM-HPME® may be protected by one or more of the following patents: US Patent
numbers 8,084,023; 8,388,947; 8,961,955.
37
Takara Bio USA, Inc., a member of the Takara Bio Group, is committed to developing high-quality
innovative tools and services to accelerate discovery. Through its Cellartis® brand, TBUSA offers a broad
range of iPS cells, highly functional human ES and iPS cell-derived hepatocytes and cardiomyocytes,
along with reagents for iPS cell culture and differentiation. We also provide customizable services ranging
from sourcing to generation to differentiation.
ISSCR Exhibit Booth: 1743
ISSCR Innovation Showcase:
“Novel system for 2D and 3D stem cell culture, differentiation and
scale up - from research to clinical.”
Pluripotent stem cells hold great potential to advance our collective
understanding of specific diseases and to illuminate new pathways
towards improved therapeutic treatments. To advance the
utilization of human induced pluripotent stem cells for research and
clinical applications,
we have developed a novel, non-colony, monolayer stem cell culture system. In contrast to colony culture,
this innovative monolayer culture system maintains high levels of stemness and suppresses any
unwanted differentiation in your stem cell culture, all in a robust, easy-to-use, reproducible system.
Available in 2D, 3D, feeder-free, xeno-free, and GMP-grade formats, this system enables you to select
the combination of features that best suit your specific research needs. This new stem cell culture system
provides the ideal pluripotent, homogeneous starting population of iPS cells necessary for the success
of downstream applications, such as directed differentiation into various cell lineages, single cell cloning
and selection, and 3D spheroid scale-up for research and large-scale clinical research.
Contact Information:
Takara Bio USA, Inc.
1290 Terra Bella Avenue
Mountain View, CA 94043
1.800.662.2566
www.clontech.com
38
Takasago Fluidic Systems provides fluidic technology to automate
various culture medium supply systems.
3D Perfusion System
•
A new perfusion system that utilizes cell culture inserts and enables 3-dimensional perfusion that can permeate
through tissues or spheroids, making the culture closer to an in-vivo condition.
For
a 6-well
Plate
6-well Plate


Medium reaches deeper parts of
tissues or spheroids.
Secretions from upstream cells
can act on downstream cells.
Portable Medium Exchange System
•
Automates the process of medium exchange at
a specific time interval.
•
•
Battery-operated. Usable in an incubator.
A standard 6-well plate can be used with this
system.
•
Wells are observable on a microscope.
For
a 6-well
Plate
Automatic Optical Cell Inspection and Removing
Device
•
•
Detects deformed cells by image analysis and then
automatically destroys them by a laser beam.
Under development by
SINFONIA TECHNOLOGY Co., Ltd.
Takasago Fluidic Systems
1900 West Park Drive, Suite 280, Westborough, MA 01581
U.S.A.
Tel +1 508 983 1434 Fax +1 508 983 1401
E-mail: [email protected] URL: http://www.takasago-fluidics.com/
39
The Company of Biologists
The Company of Biologists is a not-for-profit publishing organisation dedicated to supporting and
inspiring the biological community through specialist journals, meetings and grants. We are run by
distinguished practicing scientists. We exist to profit science, not shareholders. We inspire new thinking
and support the worldwide community of biologists.
At the heart of what we do are our five specialist journals:
Development
http://dev.biologists.org
Development is a leading primary research journal covering the field of developmental biology. With its
long and prestigious history and its team of expert academic editors, Development is committed to
publishing cutting-edge research across the spectrum of animal and plant developmental biology.
Journal of Cell Science
http://jcs.biologists.org
Journal of Cell Science publishes cutting-edge science, encompassing all aspects of cell biology. The
journal is led by Editor-in-Chief Michael Way and a prestigious team of Editors who are research-active
academics and leaders in their respective fields; they are supported by an outstanding Editorial
Advisory Board that reflects all relevant areas in cell biology, including recently emerging fields.
Rigorous peer review and fair decisions form the bedrock of the journal and maintain Journal of Cell
Science as a solid forum for communicating the best research. S
Journal of Experimental Biology
http://jeb.biologists.org
Journal of Experimental Biology is the leading primary research journal in comparative physiology and
publishes papers on the form and function of living organisms at all levels of biological organisation,
from the molecular and subcellular to the integrated whole animal.
Our authors and readers reflect a broad interdisciplinary group of scientists who study molecular,
cellular and organismal physiology in an evolutionary and environmental context.
Disease Models & Mechanisms – Open Access journal
http://dmm.biologists.org
Disease Models & Mechanisms (DMM) is an online Open Access journal focusing on the use of model
systems to better understand, diagnose and treat human disease. The primary aim of DMM is to
promote human health by inspiring collaboration between basic and clinical researchers in translational
science, and the journal is committed to presenting rigorously peer-reviewed research that has
significant translational impact.
Biology Open – Open Access journal
http://bio.biologists.org
Biology Open (BiO) is an online Open Access journal that publishes peer-reviewed original research
across all aspects of the biological sciences. BiO aims to provide rapid publication for scientifically
sound observations and valid conclusions, without a requirement for perceived impact.
Contact information:
Jitske de Vries, Marketing Manager
The Company of Biologists
www.biologists.com
[email protected]
T:+44 (0) 1223 632 850
40
Thrive CellCultureTM 100 System (CC100) -- The Automated Cell Management System
The CC100 automates adherent cell culture processes within a closed, controlled environment
providing unattended operation and remote access to images. The system combines protocol
programmability, imaging, and analytics resulting in a reproducible process.
APPLICATIONS


Cell culture protocols:
Cell line maintenance, including; media
changes, passaging, pH monitoring and
imaging
Culture & expansion of newly derived cell
lines

Media optimization studies
Cell analysis:
 Cell growth analysis
 Cell viability testing
 Morphology analysis

Stem cell culture protocols:
During iPSC reprogramming; media
changes, incubation and image monitoring

Expansion of iPSCs

Differentiation of iPSCs

Removal of pre-differentiated cells

Protocol optimization studies
SYSTEM BENEFITS

Integrated, Environmentally Controlled Workstation

Walk-Away Protocol Execution

Data-Rich Environment; Audit Trail and Reporting
Thrive Bioscience, Inc.
11 Audubon Road
Wakefield, MA 01880 USA
978-720-8044
Media Contact: Julie Sperry, [email protected], 978-491-8506
41
JOIN US AT: ISSCR 2016 ANNUAL MEETING
June 22-25, 2016 │ San Francisco, CA│ Booth 1436
Union Biometrica, Inc. provides Large Particle Flow Cytometers (COPAS FP™ and BioSorter®) for
objects that are too large / too fragile for traditional cytometers and offer an alternative to manual sorting.
These systems analyze and sort objects based on size and fluorescent parameters. Automating this
process offers increased speed, sensitivity, quantification, and repeatability of experiments.
Visit us in Booth# 1436 to learn about our BioSorter and LP Sampler™ technologies.
BioSorter – multi-range, large particle flow
cytometer for gentle sorting of 10-1500 µm
particles.
•
Large cells / cell clusters –
cardiomyocytes, adipocytes, iPS cells,
EB’s, pancreatic islets, duct cells. No
need to fragment clusters into single
cells. Sorting intact cell clusters
maintains natural cell-cell interactions.
This multi-range cytometer can also be used as a shared instrument in a core lab for sorting other
large objects including:
•
•
•
•
Small model animals - C.elegans, D.melanogaster, D.rerio.
Small plant models - Arabidopsis, other plant pollen, protoplasts and calli.
Encapsulated cells and bead-based libraries.
Other - Aspergillus, mosquitoes and bacteria.
LP Sampler - an autosampler that automatically loads samples
from multiwell plates of many different formats such as 24-, 96-,
384-well to the BioSorter for analysis and re-sorting.
Union Biometrica, Inc. ▪ www.unionbio.com
USA: 84 October Hill Rd, Holliston, MA 01746 Tel: +1-508-893-3115
Europe: Cipalstraat3, B-2440, Geel, BELGIUM Tel: +34 (687) 859 190
Email: [email protected]
42
GrowDex® - The Natural Support for 3D Cell Culture
GrowDex® is a natural hydrogel derived from wood-based cellulose free from any
human or animal derivatives for use in cell based research and drug discovery. It
is biocompatible with cells and tissues and, due to the presence of nanofibrils,
closely resembles an extracellular matrix (ECM) offering mechanical support for
3D cell growth.
GrowDex® can be tuned to provide optimal support for a plethora of cell types, including but not
limited to, stem cells (iPS, ES, MSC), cancer cell lines and hepatocytes. Cells and small
molecules, such as nutrients and oxygen, are free to move and diffuse through the hydrogel
making it ideal environment to study cell behaviors such as proliferation rates, spheroid formation
and cell differentiation.
Cells can be recovered from GrowDex® by simple enzymatic degradation of the
hydrogel (products non-toxic) while retaining their 3D structure and ready for further
experimental investigation.
A) Human pluripotent stem cells form 3D spheroids in 0.5% GrowDex® hydrogel, and B)
remain alive throughout the culture C) HepG2 spheroid in silica. Images from Yan-Ru Lou
(Ph.D.), University of Helsinki, Finland
GrowDex® 2016 Highlights
Innovation award
UPM’s GrowDex® hydrogel wins the Chemical Industry Federation of Finland
Innovation Award 2016. The award is handed out to innovations which are seen
to be of great benefit to the well-being of both humans and the environment and
make a commercial success on an industrial scale.
Improved cancer models
The Institute for Molecular Medicine Finland (FIMM) and UPM Biochemicals
have started a joint research project with the purpose of investigating the
applicability of UPM's cellulose-based GrowDex® hydrogel for cancer research
for personalised medicine.
For more information, please visit www.growdex.com
Contact: Pia Nilsson, Head of GrowDex Business, UPM Biochemicals,
[email protected] or [email protected]
43
Contact:
Robert Drape, Executive Director (reachable
at ISSCR via mobile: 608-577-9221)
ISSCR Exhibitor Booth #:
1336
Website:
www.wicell.org
Announcements:
A portion of the 1,500 NHLBI “Next Gen” iPS cell lines are being made available the week of
ISSCR. Hear more at WiCell’s Focus Session entitled “Humanity in a Dish”, or stop by the
WiCell booth for information on the cell lines.
About WiCell:
A recognized world leader in pluripotent stem cell banking and characterization, WiCell provides
the stem cell community with high quality cell lines as well as accurate and reliable cytogenetic
testing.
Products and Services offered:
-
Human pluripotent cell lines (ES, iPS, disease model, and modified) and differentiated
progenitors
-
Cell line distribution services for researchers and companies generating cell lines
-
Cytogenetic testing services (G-banded karyotyping, SKY, FISH, fastFISH, CGH
microarray, SNP microarray, and Identity testing via STR)
-
Custom quality control testing and cell banking services are available by request
44
Worthington Launches Celase® GMP an Avian and Mammalian Tissue-free Collagenase and
Neutral Protease Enzyme Blend Produced Under GMP Guidelines
New enzyme grade is now available for use in a wide range of applications from
initial animal research through clinical trials.
LAKEWOOD, NJ – Worthington announced today at the ISSCR, the launch of the new Celase®
GMP Enzyme product offering. Manufactured by Cytori Therapeutics, this product line is ideal
for cell isolation studies for laboratories looking to facilitate a smooth transition from bench and
animal research to downstream clinical applications.
Celase® GMP is a proprietary enzyme containing a unique blend of collagenase, neutral
protease and buffer salts that are produced using avian and mammalian tissue-free raw
materials, aseptically processed, sterile filtered and highly purified under GMP guidelines. A
single, sterile, ready to use enzyme containing both collagenase and a neutral protease is ideal
for a wide range of adipose stem cell, biomedical and bioprocessing applications.
“This new Celase® GMP product offering is a cost-effective option for laboratories looking for a
high-quality GMP enzyme to support their pre-clinical research,” said James Zacka, vice
president at Worthington. “We believe the sooner a researcher recognize a potential for a
clinical application it is to their long term regulatory benefit to qualify and use a GMP or
equivalent grade of enzyme”
Not all research applications required the use a GMP grade enzyme in early phase studies.
However, the recent FDA guidance issued for tissue and cell products specifically cite that GMP
grade reagents should be used in drug-type validated processes. Subsequently, both
regenerative medicine researchers and clinicians are now looking for GMP quality products with
a smoother regulatory approval process as the goal.
“The Cytori Celase® GMP enzyme is currently used in US FDA approved clinical trials. We are
excited to offer a foundational and versatile enzyme for advancing adipose-based research
programs from pre-clinical to clinical levels while eliminating the need to perform costly and time
consuming bridging studies,” said Jason Streeter, quality engineer at Worthington.
For more information contact: James Zacka at 800.445.9603/732.942.1660
About Worthington Biochemical Corporation
Founded in 1947, Worthington Biochemical Corporation is an industry leader in the
development and production of high quality purified enzymes, proteins, nucleic acids and cell
isolation kits for life science research, diagnostics and biotechnology applications. An ISO9001
Certified, primary manufacturer Worthington meets enzyme requirements from research to
larger scale bulk bioprocessing and OEM applications. Worthington Biochemical Corporation is
a privately held company, headquartered in Lakewood, NJ and has worldwide distribution
through a network of exclusive distributors. Go to: Worthington-Biochem.com
45